Abstract
The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of action and also overcome the associated siRNA delivery limitations. The topical delivery of siRNA has been achieved using viral or nonviral methods, and the combination of non-viral methods with an active permeation method such as iontophoresis, sonophoresis or microneedles for the treatment of skin disorders. These delivery approaches have been tested in a preclinical setup and few cases the results have shown promise for clinical trials. This review provides an update on the advances in the non-viral delivery approaches for siRNA delivery for skin disorders and use of various delivery approaches for efficient delivery at the disease site.
Keywords: siRNA, skin disorders, topical, nanoparticle.
Current Pharmaceutical Design
Title:Progress in Topical siRNA Delivery Approaches for Skin Disorders
Volume: 21 Issue: 31
Author(s): Mohammed Aldawsari, Mahavir B. Chougule and R. Jayachandra Babu
Affiliation:
Keywords: siRNA, skin disorders, topical, nanoparticle.
Abstract: The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of action and also overcome the associated siRNA delivery limitations. The topical delivery of siRNA has been achieved using viral or nonviral methods, and the combination of non-viral methods with an active permeation method such as iontophoresis, sonophoresis or microneedles for the treatment of skin disorders. These delivery approaches have been tested in a preclinical setup and few cases the results have shown promise for clinical trials. This review provides an update on the advances in the non-viral delivery approaches for siRNA delivery for skin disorders and use of various delivery approaches for efficient delivery at the disease site.
Export Options
About this article
Cite this article as:
Aldawsari Mohammed, Chougule B. Mahavir and Babu Jayachandra R., Progress in Topical siRNA Delivery Approaches for Skin Disorders, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/1381612821666150911093606
DOI https://dx.doi.org/10.2174/1381612821666150911093606 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member:
Current Respiratory Medicine Reviews Targeting the Most Upstream Site of Wnt Signaling Pathway Provides a Strategic Advantage for Therapy in Colorectal Cancer
Current Drug Targets Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers The Role of Mesothelin in Tumor Progression and Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Current Molecular Medicine Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Physico-Chemical Properties Mediating Reproductive and Developmental Toxicity of Engineered Nanomaterials
Current Medicinal Chemistry Gene Therapy for Lung Diseases Development in the Vector Biology and Novel Concepts for Gene Therapy Applications
Current Molecular Medicine Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry